James A. Eastham, MD, FACS, presented “Active Surveillance: Intermediate Disease and High-Volume Grade Group 1 Prostate Cancer” during the 26th Annual Southwest Prostate Cancer Symposium conference on April 13, 2023, in Scottsdale, Arizona.
How to cite: Eastham, James A. “Active Surveillance: Intermediate Disease and High-Volume Grade Group 1 Prostate Cancer.” April 13, 2023. Accessed Aug 2024. https://grandroundsinurology.com/active-surveillance-intermediate-disease-and-high-volume-grade-group-1-prostate-cancer/
Active Surveillance: Intermediate Disease and High-Volume Grade Group 1 Prostate Cancer – Summary
James A. Eastham, MD, FACS explores the role of active surveillance as management for patients with intermediate-risk prostate cancer and those with high-volume, low-grade tumors. Intermediate-risk prostate cancer patients with Gleason score 3+4, PSA levels between 10 and 20 ng/mL, or clinical stage T2b-T2c, and those with high-volume Grade Group 1 disease (biopsy cores containing Gleason 6) are the most appropriate patients for active surveillance.
Dr. Eastham delves into the protocols for active surveillance, including the frequency of PSA testing, digital rectal exams, imaging, and repeat biopsies. He underscores the importance of patient adherence to surveillance schedules.
Dr. Eastham acknowledges the ongoing debate about the safety and efficacy of active surveillance for higher-risk categories. In his presentation, he considers evidence both supporting and questioning this approach.
About the 26th Annual Southwest Prostate Cancer Symposium:
This conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
James A. Eastham, MD, FACS, is the Peter T. Scardino Chair in Oncology and Chief of the Urology Service in the Department of Surgery at Memorial Sloan-Kettering Cancer Center in New York. Dr. Eastham received his medical degree from the University of Southern California, Los Angeles. He completed an Internship in General Surgery and a Residency in Urology at Los Angeles County+USC Medical Center. He went on to complete a Fellowship in Urologic Oncology at Baylor College of Medicine in Houston, Texas. Prior to his appointment at Memorial Sloan-Kettering Cancer Center, Dr. Eastham was an Assistant and Associate Professor in the Department of Urology at Louisiana State University in Shreveport and Chief of Urology at Overton-Brooks Veterans Administration Medical Center in Louisiana.
Dr. Eastham’s research has focused on the prevention and treatment of prostate cancer, and he has a particular interest in improving oncologic and quality-of-life outcomes after radical prostatectomy. He has authored or co-authored over 300 articles which have appeared in peer-reviewed journals such as the Journal of the American Medical Association, the Journal of Urology, the Journal of Clinical Oncology, Urology, and Transplantation. In addition, he has authored numerous book chapters, reviews, monographs, and abstracts. He is a Fellow of the American College of Surgeons and a member of several professional societies, including the American Urologic Association, the Society of Urologic Oncology, and the Societé Internationale D’Urologie.
